Xilio Therapeutics, Inc. (XLO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001840233 0001840233 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10,
How this was made
The 30-second read
Why it matters
The only fundamental shareholder-approved item is the amended and restated 2021 Stock Incentive Plan, which changes how shares underlying outstanding prefunded warrants are counted for the plan’s annual evergreen increase. Director class rebalancing is contingent/administrative and explicitly states no compensation changes and no compensation due.
Market read
Traders may monitor dilution expectations from the equity-plan evergreen mechanics, but the director reshuffle itself is unlikely to drive material repricing without additional financial/clinical catalysts.
What to watch
The filing does not quantify the incremental share capacity added by the amended evergreen calculation; without that number, dilution impact may be harder to price immediately.
Background
This SEC 8-K reports Item 5.02 (director/officer departure and election/appointment) and Item 5.07 (annual meeting voting results) for Xilio Therapeutics’ June 10, 2026 annual meeting.
Ticker impact
Xilio Therapeutics rebalanced its board by resigning and immediately reappointing Daniel Curran as a different class director, and stockholders approved an amended 2021 equity plan.
Near-term impact likely limited; any move would more likely reflect dilution/option-plan overhang rather than the director reshuffle itself.
The filing discloses no new clinical/financial results or deal terms; the only potentially tradable fundamental change is shareholder approval of an equity-plan amendment that can expand share issuance capacity.
Market effects
For small-cap biotech, equity-plan evergreen approvals can modestly influence perceived dilution risk across the sector, but this is company-specific and not a sector-wide regulatory/clinical catalyst.
None.
None.
Counterpoint
The director class rebalancing may be purely structural to comply with charter provisions, so traders may overreact to governance language while ignoring that compensation terms did not change.
Key entities
- issuerXilio Therapeutics, Inc.
Nasdaq-listed company filing the 8-K; board rebalanced and stockholders approved amended 2021 equity plan.
- directorDaniel Curran, M.D.
Resigned as Class II director contingent on reappointment; immediately reappointed as Class III director after rebalancing.
- equity_planAmended and Restated 2021 Stock Incentive Plan
Stockholder-approved amendment/restatement; adds shares underlying outstanding prefunded warrants to evergreen increase calculation.
